👉 Getting professional - Intestinal Ultrasound (IUS)
“How do we integrate IUS and what’s the cost?” There’s growing demand for seamless data access and clinical trial integration. The data’s big, complex, and needs to be moved around in the growing number of trials. Robust solutions, remote training, and good record keeping are needed yesterday!
👉 Product Launch at DDW: Bridge!
Motilent has just the solution: Bridge, a fast and simple way to securely store and transfer your imaging for training, trials and clinical practice. Send data straight to your Entrolytics for storage, QC and prep for studies. See our demo here: https://lnkd.in/eNh3gsf4
👉 Hot topic - Fibrostenotic Crohn’s Disease
The big question: How do we measure treatment response?
While we can’t quantify fibrosis directly, MRI lets us infer meaningful changes in structure and function through length, volume, dilation, and peristaltic activity. Motilent supports dozens of studies, clinical trials and the FIBROTARGET consortium getting us ready for antifibrotic therapies. Get an update on motility imaging in FSCD in the comments below - a recent paper from AUMC.
👉 Trial results - GIQuant gaining traction
Early results from the 5-year CONTEXT Trial showed that GIQuant influenced clinical impressions in nearly 50% of cases, while also helping reduce scan times by decreasing reliance on IV gadolinium. Across multiple studies in children and adults inter-reader agreement is good to excellent. FDA Cleared and CE Marked, GIQuant is available to assist trained radiologist in assessing disease activity.
👉 Entrolytics: The operating system for modern gastroenterology appeared in 24 abstracts in May
Now serving 172 active projects across IUS, endoscopy, MRI, and capsule endoscopy studies with structured reporting. 3D modeling and structured reporting are seeing ever-increasing use. If it involves imaging of the GI tract from Scleroderma to pouchitis, we have a workflow and toolset to help you answer difficult questions definitively.
👉 Business as usual: Motilent is a self-supporting, mission-driven medical technology company dedicated to transforming how we see the gut. Amid shifts in US research funding priorities, Motilent remains committed to supporting innovative work including the CAMEO trial in pediatric Crohn’s disease and a range of other studies impacted by changes in NIH funding.
As always, it was fantastic to support our collaborators at their posters and talks and to catch up at the Motilent booths!